Citadel Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Citadel Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.89M	Sell	181,356 -181,977	-50%	-$2.79M	﹤0.01%	5169
2026 Q1	$5.04M	Buy	363,333 +306,381	+538%	+$4.88M	﹤0.01%	4321
2025 Q4	$925K	Buy	56,952 +28,868	+103%	+$471K	﹤0.01%	7575
2025 Q3	$420K	Sell	28,084 -772,605	-96%	-$9.41M	﹤0.01%	9546
2025 Q2	$9.33M	Buy	800,689 +656,351	+455%	+$5.96M	﹤0.01%	3126
2025 Q1	$1.07M	Sell	144,338 -82,644	-36%	-$635K	﹤0.01%	6809
2024 Q4	$1.36M	Buy	226,982 +17,556	+8%	+$96.8K	﹤0.01%	6418
2024 Q3	$1.07M	Sell	209,426 -192,696	-48%	-$840K	﹤0.01%	6744
2024 Q2	$1.46M	Buy	402,122 +320,224	+391%	+$1.02M	﹤0.01%	5886
2024 Q1	$263K	Buy	81,898 +79,027	+2,753%	+$306K	﹤0.01%	9757
2023 Q4	$14.1K	Sell	2,871 -141,121	-98%	-$644K	﹤0.01%	12897
2023 Q3	$785K	Sell	143,992 -570,530	-80%	-$3.77M	﹤0.01%	7078
2023 Q2	$4.79M	Sell	714,522 -87,981	-11%	-$654K	﹤0.01%	3716
2023 Q1	$7.09M	Buy	802,503 +259,225	+48%	+$2.29M	﹤0.01%	3269
2022 Q4	$4.15M	Sell	543,278 -292,537	-35%	-$2.28M	﹤0.01%	4179
2022 Q3	$5.95M	Buy	835,815 +434,246	+108%	+$4.09M	﹤0.01%	3578
2022 Q2	$3.25M	Buy	401,569 +199,698	+99%	+$1.76M	﹤0.01%	4613
2022 Q1	$2.8M	Buy	201,871 +31,851	+19%	+$501K	﹤0.01%	5347
2021 Q4	$4.77M	Buy	170,020 +43,704	+35%	+$1.34M	﹤0.01%	4367
2021 Q3	$4.29M	Buy	126,316 +79,813	+172%	+$2.89M	﹤0.01%	4598
2021 Q2	$1.9M	Sell	46,503 -311,290	-87%	-$12.1M	﹤0.01%	6744
2021 Q1	$14.4M	Buy	357,793 +352,101	+6,186%	+$19.1M	﹤0.01%	2424
2020 Q4	$337K	Sell	5,692 -8,161	-59%	-$421K	﹤0.01%	8867
2020 Q3	$674K	Sell	13,853 -36,887	-73%	-$1.55M	﹤0.01%	6759
2020 Q2	$2.46M	Buy	50,740 +14,763	+41%	+$538K	﹤0.01%	4199
2020 Q1	$999K	Sell	35,977 -21,827	-38%	-$609K	﹤0.01%	5336
2019 Q4	$1.73M	Sell	57,804 -60,279	-51%	-$1.73M	﹤0.01%	4654
2019 Q3	$3.65M	Sell	118,083 -116,288	-50%	-$4.75M	﹤0.01%	3555
2019 Q2	$11.3M	Buy	+234,371	New	+$10.4M	0.01%	2038

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Citadel Advisors's ADPT Position: Q2 2026 in Review

Citadel Advisors reduced its Adaptive Biotechnologies (ADPT) stake by 50% in Q2 2026, selling an estimated $2.79M and leaving 181,356 shares worth $3.89M. The position accounts for ﹤0.01% of the portfolio, ranked #5169.

Citadel Advisors first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. The position peaked at $14.4M in Q1 2021. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Citadel Advisors held 181,356 shares of Adaptive Biotechnologies worth $3.89M as of Q2 2026.
Citadel Advisors sold 181,977 Adaptive Biotechnologies shares in Q2 2026, an estimated $2.79M.
Adaptive Biotechnologies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5169 holding.
Citadel Advisors first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
Citadel Advisors's Adaptive Biotechnologies position peaked at $14.4M in Q1 2021.
301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.